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doi:10.1016/j.ejvs.2008.11.025Abstract Objective: Endovascular repair for degenerative aortic aneurysms is well estab-
lished, but its role in those with infective pathology remains controversial. This study aims
to assess the durability of endovascular repair with a review of our midterm results.
Method: A retrospective analysis of a prospectively maintained endovascular database
(1998e2008) was conducted, which identified 673 consecutive patients with aortic aneurysms.
Results: Nineteen patients (2.8%) were identified with infected aortic aneurysms, in which
there were a total of 23 separate aneurysms (16 thoracic and seven abdominal). Six patients
(32%) presented with rupture. Eleven patients (58%) had received antibiotics preoperatively
for a median duration of 11 days (1e54 days). Fifteen of the 19 (79%) had positive blood
cultures, with Staphylococcus aureus being the most common organism.
All 19 patients underwent endovascular repair. There were three Type I endoleaks (one
requiring conversion to open repair) and two Type II endoleaks. One patient developed transient
paraplegia, resolved by cerebrovascular fluid (CSF) drainage, and one patient had a stroke.
The 30-day mortality was 11%, and survival at median follow-up of 20 months (0e83 months)
was 73%. All eight deaths in the series were related to aneurysm.
Conclusion: Endovascular treatment of infective aortic pathology provides an early survival
benefit; however, concerns over on-going graft infection remain.
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ty for Vascular Surgery. PublisheMycotic aneurysms have a relative incidence of 1e3% in
large aortic series, and represent one of the most chal-
lenging clinical problems for the vascular surgeon.1 The
classical symptoms of fever, malaise and leucocytosis are
nonspecific, and this often leads to late diagnosis and
treatment.2 In addition, these aneurysms have a relative
predilection for the visceral and thoracic segments of the
aorta, which further complicates management.d by Elsevier Ltd. All rights reserved.
Table 1 Patient demographics
NZ 19 Percentage (%)
Co-morbidities
Diabetes mellitus 2 11
Smoking 8 42
Chronic renal failure 1 5
Chronic disease 4 21
Recent infection
Gastrointestinal 3 16
Musculoskeletal 2 11
Urinary 1 5
Respiratory 1 5
Previous aortic surgery 6 32
Recent operation (<6 weeks) 2 11
Table 2 Infective status
N Percentage (%)
Fever (>38 C) 8 42
Leucocytosis (>11.0 109 cells l1) 9 47
Pain 7 37
C-reactive protein (>5 mg l1) 9 47
Positive blood culture 15 79
Pre-operative antibiotic 11 58
Presentation with rupture 6 32
Saccular aneurysm morphology 23 100
408 R.E. Clough et al.Traditional treatment consisted of open surgical repair
with resection of the infected segment, extensive local
debridement and in situ or extra-anatomical bypass.
Despite advances in peri-operative management and anti-
microbial therapy, the mortality and morbidity remain high,
in the region of 21e36%.3,18
Endovascular repair of degenerative thoracic and abdom-
inal aneurysms is well established; however, placing an endo-
vascular graft in an infected field remains counter-intuitive.
There are an increasing number of reports in the literature of
successful endovascular repair of mycotic aneurysms, but the
numbers are small and the follow-up is short.4e7
The current study aimed to assess the durability of
endovascular repair of mycotic aortic aneurysms with
a review of our midterm results.
Methods
A review of a prospectively maintained database of
patients undergoing endovascular repair of thoracic and
abdominal aneurysms in our institution was conducted. The
database covered a 10-year period from 1998 to 2008.
Aortic infection was defined by two or more of the
following: clinical evidence of infection (fever, pain, leu-
cocytosis), positive blood culture or characteristic radio-
logical appearance (rapidly growing or saccular aneurysm).
Patients with pathology isolated solely within the ascending
aorta or visceral segment were excluded from the study. All
patients were considered unfit for open surgical repair.
There was no change in stent-graft selection or method of
device sizing, compared with the treatment of uninfected
aortic aneurysms within our practice.
Our follow-up protocol consisted of clinical (fever/pain),
imaging (computerised tomography, CT, with intravenous
contrast) and haematological (C-reactive protein (CRP)/
white cell count (WCC)) analysis at 3, 6 and 12 months and
then annually thereafter. Data were obtained from systems
within our hospital, from the patient’s general practitioner
(community doctor) and from the patient’s local hospital
when applicable. Data were recorded on Microsoft Excel,
and statistical analysis was performed with Prism software.
Analysis of frequencies and survival was performed.
Results
During the 10-year interval, 673 patients underwent endo-
vascular repair of thoracic or abdominal aneurysms. A total
of 19 patients (7 men and 12 women) were identified with
infected aortic aneurysms giving an incidence of 2.8%. The
median age of these patients was 70 years (range: 39e79
years). The median clinical follow-up was 20 months
(range: 0e83 months). The patient demographics are
illustrated in Table 1.
Six patients had evidence of rupture (32%). Twelve
patients (63%) had fever, pain or leucocytosis (Table 2).
Eleven patients (58%) had received antibiotics preopera-
tively for a mean duration of 11 days (range: 1e54 days).
Fifteen patients (79%) had positive blood cultures, with
Staphylococcus aureus being the most common organism
(Fig. 1). Of the 19 patients, seven patients (37%) had one or
more co-morbid factors associated with a degree ofimmuno-compromise and nine had a recent infection or
operation (47%).
A total of 23 aneurysms were identified in the 19 patients:
16 thoracic and seven abdominal. Pre-operative imaging (CT
with intravenous contrast (17 patients), angiography
(patient too unstable for CT/in addition to CT) (four
patients) and oesophago-gastro-duodenoscopy (for visual-
isation of fistula) (three patients)) revealed that all
aneurysms were saccular (Fig. 2) and also revealed the
presence of six fistulae (aorto-oesophageal (three patients),
aorto-cutaneous (one patient) and aorto-bronchial (two
patients)).
All patients underwent endovascular repair. The details
of devices used and the procedural data are included in
Table 3. Cerebrospinal fluid (CSF) drainage was not used
preoperatively.
Additional procedures were required in six patients and
included: carotidecarotid bypass to extend the proximal
landing zone (three patients), femoralefemoral bypass
after insertion of an aorto-uni-iliac device (two patients)
and left subclavian artery embolisation for a Type II endo-
leak (one patient).
The median hospital stay was 19 days (range: 2e67
days), with three patients requiring intensive care admis-
sion for a median duration of 15 days (range: 2e23 days).
Early outcome (<30 days post-procedure)
Mortality
The 30-day mortality (Table 4) was 11% (two out of 19). One
death was due to rupture of a further mycotic aneurysm,
Figure 1 Organisms from blood culture.
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fistula and multiple organ failure secondary to sepsis. The
former was our first case; the primary, symptomatic
aneurysm was located within the thoracic aorta and the
secondary, initially asymptomatic, aneurysm was located
distally just above the aortic bifurcation. Initial imaging
did not include the entire aorta, and so the second
aneurysm was not foreseen. This death lead to a change
in our practice and now all patients undergo imaging of
the entire aorta.
Morbidity
Postoperative recovery was complicated by cardiac (acute
coronary syndrome (two patients), arrhythmia (one
patient)), respiratory (pneumonia (two patients) and
pulmonary embolus (one patient)) and neurological
complications (stroke (one patient) and paraplegia (one
patient)). The single case of paraplegia resolved with
immediate CSF drainage.Table 3 Procedural data and devices
Median Range
ASA grade 3 2e4
Procedure duration (min) 85 50e540
Radiation dose (Gym2) 135 49.8e361.0
Contrast volume (ml) 107 20e240
Blood loss (ml) 322 10e1800
Stent grafts n
Cook Group Inc. (Bloomington, IN) 8
Tx2 3
AAA 3
Aorto-uni-iliac 2
Medtronic Inc (Santa Rosa, CA) 4
AneuRx 2
Talent 2
W.L. Gore & Associates
(Sunnyvale, CA)
11
Tag 9
Excluder 2Endoleak
Endoleak occurred in four patients: two proximal Type I
endoleaks (one required conversion to open repair and one
was sealed with a proximal extension cuff), one distal Type
I endoleak (sealed spontaneously by day 6) and two Type II
endoleaks arising from the left subclavian artery (one
required embolisation and the other sealed spontaneously).
Secondary procedures
Further endovascular grafts were deployed in two patients:
one on day 39 for a further mycotic abdominal aortic
aneurysm, the other on day 28 for further bleeding from an
aorto-oesophageal fistula (Fig. 3).
Late outcome (>30 days post-procedure)
Mortality (Table 4)
Cumulative survival was 73%, 73% and 29% at 1, 4 and 5
years, respectively.Figure 2 CT angiogram illustrating thoracic saccular
aneurysm.
Figure 3 CT angiogram illustrating evidence of on-going
infection after endoluminal repair.
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the first year, and all were due to fistulae e one new (aorto-
oesophageal) and two recurrent (aorto-oesophageal and
aorto-cutaneous) fistulae. A further death occurred after 4
years due to sepsis of unknown origin. The remaining two
were in the 6th and 7th year of follow-up and were due to
recurrent fistulation (aorto-bronchial and aorto-
oesophageal).
Morbidity
There was no reported late morbidity.
Endoleak
No late endoleak was detected.Table 4 Deaths
Sex Age Primary diagnosis Complication Re-in
M 62 Thoracic aorta
aneurysm
Further aortic
aneurysm
None
F 74 Thoracic aorta
aneurysm
Aorto-oesophageal
fistula
None
F 68 Aorto-oesophageal fistula Recurrence Furt
day
M 64 Thoracic aorta
aneurysm
Aorto-oesophageal
fistula
Furt
day
F 69 Aorto-cutaneous fistula Recurrence None
F 63 Thoracic and abdominal
aorta aneurysms
Sepsis None
F 67 Aorto-bronchial fistula Recurrence None
F 58 Aorto-oesophageal fistula Recurrence Furt
daySecondary procedures
Two patients required further stent grafts: one on day 39
for recurrence of an aorto-oesophageal fistula, the other in
the 5th year for recurrence of an aorto-oesophageal fistula.
Antibiotic therapy
The antibiotic regime was devised on a case-by-case basis
with close collaboration with the microbiology department.
Broadly speaking, if there were positive blood cultures,
then the treatment regime was organism-specific; other-
wise it was broad spectrum. Methicillin-resistant Staphy-
lococcus aureus (MRSA) was not routinely covered, unless
there were positive cultures or a high index of suspicion.
Patients received initial high-dose intravenous therapy and
were then discharged on a course of oral antibiotics. The
antibiotics were stopped when clinical markers (fever/
pain), haematological (CRP/WCC) and imaging (CT with
intravenous contrast), were within normal limits. The
median duration of antibiotics was 42 days (range: 28e91
days).
Discussion
Mycotic aneurysms represent a relatively small proportion
of our endovascular series, but provide the greatest
complexity in terms of diagnosis and clinical management.
The classical features of fever, pain and leucocytosis were
present in the majority, and resulted in late presentation
with a high incidence of aortic rupture. Despite treatment
of 11 of 19 patients with antibiotics preoperatively,
infections were detected in 79% of our series, with virulent
organisms such as S. aureus and Salmonella forming the
greatest proportion. A high number of patients were
immuno-compromised with a history of previous aortic
surgery and recent systemic infection. Pre-operative
imaging revealed classical saccular aneurysms in all, with
a relative predilection to the thoracic segment and multiple
aneurysms in four of the 19 patients.tervention Cause of death Number of days
after initial
procedure
Rupture of further
aortic aneurysm
4
Aorto-oesophageal fistula 23
her stent-graft,
28
Aorto-oesophageal fistula 39
her stent-graft,
39
Aorto-oesophageal fistula 49
Aorto-cutaneous fistula 163
Multiple organ failure
secondary to sepsis
1748
Aorto-bronchial fistula 1944
her stent-graft,
1560
Aorto-oesophageal fistula 2289
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aneurysm. Four occurred in the six patients who had
initially presented with an aortic fistula, thereby almost
doubling the mortality rate in the group compared to that
for simple aneurysm. The cohort is too small and hetero-
geneous to allow meaningful statistical evaluation;
however, crude analysis suggests that, in addition to the
presence of a fistula, patients presenting with rupture and
those in whom a stent graft was deployed in the presence of
a fever tended to have problems with persistent infection.
Patients who received antibiotics for more than 3 days
preoperatively tended to be relatively protected from long-
term infection. These findings are similar to those from the
recently published systematic review.8
Analysis of other patient-related features, including
organism type, did not reveal any other associations.
Our survival analysis illustrates promising early and
midterm results; however, it is difficult to find a suitable
control to which these results can be compared. Within our
centre, over this 10-year period, we have not undertaken
any open mycotic, thoracic aorta repairs and have
performed only four infrarenal extra-anatomical repairs. Of
the latter, two have remained well during follow-up and
two have died of aneurysm-related causes. Crude compar-
ison with data from the literature would suggest that
endovascular repair has the early and midterm advantage
but that long-term survival may be better with open
surgical repair.
Open repair is a well-established means of treating this
pathology, and traditionally consists of aneurysm resection,
extensive local debridement and extra-anatomical
bypass.9,10 However, initial survival tends to be poor with
high rates of aortic stump rupture, amputation and
cardiovascular morbidity.11,12 In situ repair with prosthetic
material, or autologous or cryopreserved conduit, have
demonstrated promising results, and this suggests that the
placement of foreign material within the infected area may
be feasible.9,13,14 This is the case with endovascular repair,
and early follow-up from small series have demonstrated
promising results. However, patients with a primary or
secondary aortic fistula, or infected prosthetic material
from a previous open repair, tend to do worse.15 In this
series, results for individuals with previous prosthetic
repair were comparable with primary aortic infection, but
those with aortic fistulae had evidence of on-going infec-
tion and high rates of re-intervention.
It seems likely that aortic fistulae form a distinct sub-
group, and methods of open repair vary depending upon
the area of the gastrointestinal or respiratory tract
involved; treatment focuses on obliteration of the fistula
tract, excision of infected material and adequate repair of
both lumens.16 Endovascular repair is not able to address
the pathological communication and, therefore, the stent
graft is subjected to a continuing source of infection.
Acceptable results have been achieved with long-term,
organism-specific antibiotics, but many authors conclude
that, for this pathology, endovascular repair may only be
a temporising method, with definitive open repair once
haemodynamic stability and infective control has been
gained. 15,17 Within our series, these patients were not fit
enough for open repair, and so a staged procedure was not
an option. However, on the basis of these results, we wouldrecommend a second-stage procedure, although its timing
and patient compliance may be an issue.
Lastly, antibiotic therapy is clearly crucial to the
management of this pathology. These patients are
complex, and we would, therefore, advocate a regime to
be devised on a case-by-case basis. Antibiotic type should
be determined by culture results and duration by clinical,
imaging and haematological follow-up.
Conclusion
Endovascular repair is feasible and confers promising early
and midterm results; however, long-term durability is yet to
be established. Patients presenting with an aortic fistula,
aortic rupture or with evidence of active infection may be
more likely to have problems with infection in the long
term. Antibiotic therapy is clearly crucial to the manage-
ment of this pathology, and pre-operative treatment may
be relatively protective against on-going infection. The
antibiotic regime should be devised on a case-by-case basis
with close collaboration with the microbiology department.
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